+24.4%
LIN vs GSK
+8.8%
+15.6%
-16.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | -0.4% | +1.1% | +0.8% |
| 7D | +2.1% | +0.2% | +1.9% | +2.0% |
| 30D | +6.8% | +5.4% | +1.4% | +5.7% |
| 3M | +10.4% | +0.9% | +9.5% | +10.0% |
| 6M | +3.2% | +0.7% | +2.4% | +2.8% |
| YTD | +24.6% | +5.6% | +19.0% | +20.5% |
| 1Y | +24.4% | +8.5% | +15.9% | +19.2% |
| All | +24.4% | +8.8% | +15.6% | +19.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling